Detection of doublecortin domain-containing 2 (DCDC2), a new candidate tumor suppressor gene of hepatocellular carcinoma, by triple combination array analysis

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Inokawa, Yoshikuni ^a   Nomoto, Shuji ^a   Hishida, Mitsuhiro ^a   Hayashi, Masamichi ^a   Kanda, Mitsuro ^a   Nishikawa, Yoko ^a   Takeda, Shin ^a   Sugimoto, Hiroyuki ^a   Fujii, Tsutomu ^a   Yamada, Suguru ^a   Kodera, Yasuhiro ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

DCDC2; Hepatocellular carcinoma; Methylation; Triple combination array

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DOUBLECORTIN DOMAIN CONTAINING 2 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER TISSUE; CELL STRAIN; CELL STRAIN HEPG2; CHROMOSOME 6P; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE DOSAGE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN METHYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; WESTERN BLOTTING;

AGED; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MICROTUBULE-ASSOCIATED PROTEINS; NEUROPEPTIDES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84883725525     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-65     Document Type: Article

References (45)

1. Hepatocellular carcinoma: current management and recent advances. Lau WY, Lai EC, Hepatobiliary Pancreat Dis Int 2008 7 237 257 18522878 (Pubitemid 351895383)
2. Hepatocellular carcinoma. Llovet JM, Burroughs A, Bruix J, Lancet 2003 362 1907 1917 10.1016/S0140-6736(03)14964-1 14667750 (Pubitemid 37518510)
3. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS, Radiology 1999 210 655 661 10207464 (Pubitemid 29124024)
4. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka Y, Gastroenterology 2006 131 461 469 10.1053/j.gastro.2006.05.021 16890600 (Pubitemid 44142456)
5. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB, J Clin Oncol 2006 24 4293 4300 10.1200/JCO.2005.01.3441 16908937 (Pubitemid 46630787)
6. Environmental factors and risk for hepatocellular carcinoma. Yu MC, Yuan JM, Gastroenterology 2004 127 72 78 10.1016/j.gastro.2004.09.018 (Pubitemid 39423372)
7. Novel systemic therapy options for hepatocellular carcinoma. Cusnir M, Patt YZ, Cancer J 2004 10 97 103 10.1097/00130404-200403000-00005 15130269 (Pubitemid 44403475)
8. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. El-Serag HB, Rudolph KL, Gastroenterology 2007 132 2557 2576 10.1053/j.gastro.2007.04.061 17570226 (Pubitemid 46890874)
9. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y, Tsunoda T, Furukawa Y, Nakamura Y, Cancer Res 2001 61 2129 2137 11280777 (Pubitemid 32692038)
10. Microarray-based gene expression analysis as a process characterization tool to establish comparability of complex biological products: scale-up of a whole-cell immunotherapy product. Wang M, Senger RS, Paredes C, Banik GG, Lin A, Papoutsakis ET, Biotechnol Bioeng 2009 104 76 808 10.1002/bit.22384 19489016
11. CREB3L4, INTS3, And SNAPAP are targets for the 1q21 amplicon frequently detected in hepatocellular carcinoma. Inagaki Y, Yasui K, Endo M, Nakajima T, Zen K, Tsuji K, Minami M, Tanaka S, Taniwaki M, Itoh Y, Arii S, Okanoue T, Cancer Genet Cytogenet 2008 180 30 36 10.1016/j.cancergencyto.2007.09.013 18068530 (Pubitemid 350192683)
12. Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. Kanda M, Nomoto S, Okamura Y, Nishikawa Y, Sugimoto H, Kanazumi N, Takeda S, Nakao A, Int J Oncol 2009 35 477 483 19639168
13. Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis. Nomoto S, Kanda M, Okamura Y, Nishikawa Y, Qiyong L, Fujii T, Sugimoto H, Takeda S, Nakao A, Ann Surg Oncol 2010 17 923 932 10.1245/s10434-009-0790-0 19898900
14. Leukemia inhibitory factor receptor (LIFR) is detected as a novel suppressor gene of hepatocellular carcinoma using double-combination array. Okamura Y, Nomoto S, Kanda M, Li Q, Nishikawa Y, Sugimoto H, Kanazumi N, Takeda S, Nakao A, Cancer Lett 2010 289 170 177 10.1016/j.canlet.2009.08.013 19733004
15. Reduced expression of reelin (RELN) gene is associated with high recurrence rate of hepatocellular carcinoma. Okamura Y, Nomoto S, Kanda M, Hayashi M, Nishikawa Y, Fujii T, Sugimoto H, Takeda S, Nakao A, Ann Surg Oncol 2011 18 572 579 10.1245/s10434-010-1273-z 20734148
16. Promoter hypermethylation of fibulin 1 gene is associated with tumor progression in hepatocellular carcinoma. Kanda M, Nomoto S, Okamura Y, Hayashi M, Hishida M, Fujii T, Nishikawa Y, Sugimoto H, Takeda S, Nakao A, Mol Carcinog 2011 50 571 579 10.1002/mc.20735 21268132
17. Identification of the A kinase anchor protein 12 (AKAP12) gene as a candidate tumor suppressor of hepatocellular carcinoma. Hayashi M, Nomoto S, Kanda M, Okamura Y, Nishikawa Y, Yamada S, Fujii T, Sugimoto H, Takeda S, Kodera Y, J Surg Oncol 2012 105 381 386 10.1002/jso.22135 22052684
18. Identification of the bleomycin hydrolase gene as a methylated tumor suppressor gene in hepatocellular carcinoma using a novel triple-combination array method. Okamura Y, Nomoto S, Hayashi M, Hishida M, Nishikawa Y, Yamada S, Fujii T, Sugimoto H, Takeda S, Kodera Y, Nakao A, Cancer Lett 2011 312 150 157 10.1016/j.canlet.2011.07.028 21943823
19. The evolving doublecortin (DCX) superfamily. Reiner O, Coquelle FM, Peter B, Levy T, Kaplan A, Sapir T, Orr I, Barkai N, Eichele G, Bergmann S, BMC Genomics 2006 7 188 10.1186/1471-2164-7-188 16869982 (Pubitemid 44264059)
20. Doublecortin is a microtubule-associated protein and is expressed widely by migrating neurons. Gleeson JG, Lin PT, Flanagan LA, Walsh CA, Neuron 1999 23 257 271 10.1016/S0896-6273(00)80778-3 10399933 (Pubitemid 29315722)
21. DCDC2 Is associated with reading disability and modulates neuronal development in the brain. Meng H, Smith SD, Hager K, Held M, Liu J, Olson RK, Pennington BF, DeFries JC, Gelernter J, O'Reilly-Pol T, Somlo S, Skudlarski P, Shaywitz SE, Shaywitz BA, Marchione K, Wang Y, Paramasivam M, LoTurco JJ, Page GP, Gruen JR, Proc Natl Acad Sci USA 2005 102 17053 17058 10.1073/pnas. 0508591102 16278297 (Pubitemid 41692682)
22. Strong genetic evidence of DCDC2 as a susceptibility gene for dyslexia. Schumacher J, Anthoni H, Dahdouh F, König IR, Hillmer AM, Kluck N, Manthey M, Plume E, Warnke A, Remschmidt H, Hülsmann J, Cichon S, Lindgren CM, Propping P, Zucchelli M, Ziegler A, Peyrard-Janvid M, Schulte-Körne G, Nöthen MM, Kere J, Am J Hum Genet 2006 78 52 62 10.1086/498992 16385449 (Pubitemid 41833159)
23. The genetic lexicon of dyslexia. Paracchini S, Scerri T, Monaco AP, Annu Rev Genomics Hum Genet 2007 8 57 79 10.1146/annurev.genom.8.080706.092312 17444811
24. Breakthroughs in the search for dyslexia candidate genes. McGrath LM, Smith SD, Pennington BF, Trends Mol Med 2006 12 333 341 10.1016/j.molmed.2006. 05.007 16781891 (Pubitemid 44094293)
25. Aberrant expression of the neuronal-specific protein DCDC2 promotes malignant phenotypes and is associated with prostate cancer progression. Longoni N, Kunderfranco P, Pellini S, Albino D, Mello-Grand M, Pinton S, D'Ambrosio G, Sarti M, Sessa F, Chiorino G, Catapano CV, Carbone GM, Oncogene 2013 32 2315 2324 10.1038/onc.2012.245 22733135
26. GoldenGate assay for DNA methylation profiling. Bibikova M, Fan JB, Methods Mol Biol 2009 507 149 163 10.1007/978-1-59745-522-0-12 18987813
27. The CpG island searcher: a new WWW resource. Takai D, Jones PA, In Silico Biol 2003 3 235 240 12954087 (Pubitemid 37493047)
28. The fundamental role of epigenetic events in cancer. Jones PA, Baylin SB, Nat Rev Genet 2002 3 415 428 12042769 (Pubitemid 34587077)
29. Cancer epigenetics comes of age. Jones PA, Laird PW, Nat Genet 1999 21 163 167 10.1038/5947 9988266 (Pubitemid 29070360)
30. Gene silencing in cancer in association with promoter hypermethylation. Herman JG, Baylin SB, N Engl J Med 2003 349 2042 2054 10.1056/NEJMra023075 14627790 (Pubitemid 37448928)
31. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, Harris CC, Herman JG, Nat Genet 2001 28 29 35 11326271 (Pubitemid 32405812)
32. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Wong IH, Lo YM, Zhang J, Liew CT, Ng MH, Wong N, Lai PB, Lau WY, Hjelm NM, Johnson PJ, Cancer Res 1999 59 71 73 9892188 (Pubitemid 29062959)
33. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Yang B, Guo M, Herman JG, Clark DP, Am J Pathol 2003 163 1101 1107 10.1016/S0002-9440(10)63469-4 12937151 (Pubitemid 37040145)
34. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ, Kang GH, Am J Pathol 2003 163 1371 1378 10.1016/S0002-9440(10)63495-5 14507645 (Pubitemid 37175085)
35. Increased expression of the dyslexia candidate gene DCDC2 affects length and signaling of primary cilia in neurons. Massinen S, Hokkanen ME, Matsson H, Tammimies K, Tapia-Páez I, Dahlström-Heuser V, Kuja-Panula J, Burghoorn J, Jeppsson KE, Swoboda P, Peyrard-Janvid M, Toftgård R, Castrén E, Kere J, PLoS One 2011 6 20580 10.1371/journal.pone.0020580 21698230
36. Caught up in a Wnt storm: Wnt signaling in cancer. Giles RH, van Es JH, Clevers H, Biochim Biophys Acta 2003 1653 1 24 12781368 (Pubitemid 36627817)
37. Beta-catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Wong CM, Fan ST, Ng IO, Cancer 2001 92 136 145 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0. CO;2-R 11443619 (Pubitemid 32623050)
38. Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma. Shih YL, Shyu RY, Hsieh CB, Lai HC, Liu KY, Chu TY, Lin YW, Cancer 2006 107 579 590 10.1002/cncr.22023 16795071 (Pubitemid 44107219)
39. Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma. Nomoto S, Kinoshita T, Kato K, Otani S, Kasuya H, Takeda S, Kanazumi N, Sugimoto H, Nakao A, Br J Cancer 2007 97 1260 1265 10.1038/sj.bjc.6604016 17968429 (Pubitemid 350035807)
40. SFRP1 Suppressed hepatoma cells growth through Wnt canonical signaling pathway. Shih YL, Hsieh CB, Lai HC, Yan MD, Hsieh TY, Chao YC, Lin YW, Int J Cancer 2007 121 1028 1035 10.1002/ijc.22750 17443492 (Pubitemid 47101639)
41. Epigenetic silencing of sFRP1 activates the canonical Wnt pathway and contributes to increased cell growth and proliferation in hepatocellular carcinoma. Kaur P, Mani S, Cros MP, Scoazec JY, Chemin I, Hainaut P, Herceg Z, Tumour Biol 2012 33 325 336 10.1007/s13277-012-0331-5 22351518
42. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Gallinari P, Di Marco S, Jones P, Pallaoro M, Steinkühler C, Cell Res 2007 17 195 211 17325692 (Pubitemid 46438722)
43. Functional complementation between transcriptional methylation regulation and post-transcriptional microRNA regulation in the human genome. Su Z, Xia J, Zhao Z, BMC Genomics 2011 12 5 15 22369656
44. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R 3rd, Shen L, Nimer SD, Leavitt R, Raza A, Saba H, Cancer 2006 106 1794 1803 10.1002/cncr.21792 16532500
45. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Köhler G, Wijermans P, Jones PA, Lübbert M, Blood 2002 100 2957 2964 10.1182/blood.V100.8.2957 12351408